Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.8170
-0.0260 (-3.08%)
Jun 2, 2026, 2:46 PM EDT - Market open
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$19,597
Profits / Employee
-$3,585,676
Market Cap
98.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Inovio Pharmaceuticals | 112 |
| Verrica Pharmaceuticals | 76 |
| PolyPid | 75 |
| PepGen | 56 |
| Vivani Medical | 42 |
| Biomea Fusion | 41 |
| Cardiff Oncology | 31 |
OTLK News
- 1 day ago - Outlook Therapeutics resubmits biologics license application to FDA - TheFly
- 1 day ago - Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 1 day ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 1 day ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 4 days ago - Outlook Therapeutics announces pricing of $5M registered direct offering - TheFly
- 4 days ago - Outlook to sell 8.54M shares at 58.55c in registered direct offering - TheFly
- 4 days ago - Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 days ago - Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava - TheFly